文章基本信息

标题：Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines
本地全文：下载
作者：Puthupparampil V. Scaria ; Chris G. Rowe ; Beth B. Chen 等
期刊名称：iScience
印刷版ISSN：2589-0042
出版年度：2022
卷号：25
期号：8
页码：1-19
DOI：10.1016/j.isci.2022.104739
语种：English
出版社：Elsevier
摘要：SummarySeveral effective SARS-CoV-2 vaccines have been developed using different technologies. Although these vaccines target the isolates collected early in the pandemic, many have protected against serious illness from newer variants. Nevertheless, efficacy has diminished against successive variants and the need for effective and affordable vaccines persists especially in the developing world. Here, we adapted our protein-protein conjugate vaccine technology to generate a vaccine based on receptor-binding domain (RBD) antigen. RBD was conjugated to a carrier protein, EcoCRM®, to generate two types of conjugates: crosslinked and radial conjugates. In the crosslinked conjugate, antigen and carrier are chemically crosslinked; in the radial conjugate, the antigen is conjugated to the carrier by site-specific conjugation. With AS01 adjuvant, both conjugates showed enhanced immunogenicity in mice compared to RBD, with a Th1 bias. In hACE2 binding inhibition and pseudovirus neutralization assays, sera from mice vaccinated with the radial conjugate demonstrated strong functional activity.Graphical abstractDisplay OmittedHighlights•Conjugation of RBD to EcoCRM enhanced its immunogenicity in the mouse study•Radial conjugate of RBD in AS01 induced strong pseudovirus neutralization activity•RBD conjugates induced Th-1 response with AS01 and Th-2 response with AlhydrogelImmunology; Virology.